September 22, 2014
Par Pharmaceutical Cos. has agreed to pay $100 million to Salix Pharmaceuticals Inc. unit Santarus Inc. to resolve claims Par's generic version of the heartburn drug Zegerid infringed Santarus' patents, according to a Monday filing with the U.S. Securities and Exchange Commission.
Correction: An earlier story mischaracterized the ownership of the patents. The error has been corrected.